ES2169864T3 - Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. - Google Patents

Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.

Info

Publication number
ES2169864T3
ES2169864T3 ES97926889T ES97926889T ES2169864T3 ES 2169864 T3 ES2169864 T3 ES 2169864T3 ES 97926889 T ES97926889 T ES 97926889T ES 97926889 T ES97926889 T ES 97926889T ES 2169864 T3 ES2169864 T3 ES 2169864T3
Authority
ES
Spain
Prior art keywords
endogline
monoclonal antibodies
fragments
expressed
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97926889T
Other languages
English (en)
Spanish (es)
Inventor
Ben K Seon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of ES2169864T3 publication Critical patent/ES2169864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES97926889T 1996-05-31 1997-05-30 Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. Expired - Lifetime ES2169864T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65595396A 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
ES2169864T3 true ES2169864T3 (es) 2002-07-16

Family

ID=24631047

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97926889T Expired - Lifetime ES2169864T3 (es) 1996-05-31 1997-05-30 Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.

Country Status (8)

Country Link
US (2) US5928641A (enExample)
EP (1) EP0938505B1 (enExample)
JP (1) JP4318752B2 (enExample)
AT (1) ATE214075T1 (enExample)
CA (1) CA2256413C (enExample)
DE (1) DE69710911T2 (enExample)
ES (1) ES2169864T3 (enExample)
WO (1) WO1997045450A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
WO2000042973A2 (en) * 1999-01-22 2000-07-27 The Burnham Institute Homing pro-apoptotic conjugates and methods of using same
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
DE10043481A1 (de) * 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
EP1432447A2 (en) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
AP2740A (en) * 2003-08-01 2013-09-30 Genentech Inc Anti-VEGF antibodies
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
DK1804836T3 (da) 2004-09-24 2011-01-24 Beth Israel Hospital Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP1839057B1 (en) * 2004-12-15 2010-08-25 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
MX2010011998A (es) 2008-05-02 2011-04-11 Acceleron Pharma Inc Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar.
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2657497T3 (es) 2009-08-17 2018-03-05 Tracon Pharmaceuticals, Inc. Terapia de combinación de cáncer con anticuerpos antiendoglina y agentes anti-VEGF
PT2510012T (pt) * 2009-12-09 2017-07-13 Bayer Pharma AG Anticorpos anti-c4.4a e utilizações dos mesmos
JP2014508523A (ja) * 2011-02-23 2014-04-10 ヘルス リサーチ インコーポレイテッド 抗エンドグリン抗体及び新規ヒト／マウスキメラエンドグリンを発現するノックインマウス
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP3008667B1 (en) 2013-06-14 2019-01-16 Agilent Technologies, Inc. System and method for facilitating manual sorting of objects
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
US11136581B2 (en) 2016-06-24 2021-10-05 University Of South Carolina Inhibin as targetable regulators of angiogenesis
EP3900733A1 (en) 2020-04-24 2021-10-27 Derma Innovate S.L. Src kinase activators and eng function inhibitors as enhancers of skin homeostasis/regeneration and hair growth
CN116063496B (zh) * 2022-08-15 2023-10-24 营龄(武汉)生物科技有限公司 载药的人血白蛋白联合单克隆抗体在制备药物组合物中的用途
CN115991773B (zh) * 2022-08-15 2023-11-17 营龄(武汉)生物科技有限公司 一种含有人血白蛋白的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94389A0 (en) * 1989-06-01 1991-03-10 Health Research Inc Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin

Also Published As

Publication number Publication date
US5928641A (en) 1999-07-27
DE69710911T2 (de) 2002-09-19
WO1997045450A1 (en) 1997-12-04
ATE214075T1 (de) 2002-03-15
EP0938505A1 (en) 1999-09-01
DE69710911D1 (de) 2002-04-11
JP2000511425A (ja) 2000-09-05
JP4318752B2 (ja) 2009-08-26
CA2256413A1 (en) 1997-12-04
CA2256413C (en) 2007-07-03
US6200566B1 (en) 2001-03-13
EP0938505B1 (en) 2002-03-06
EP0938505A4 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
ES2169864T3 (es) Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
CO2020015084A2 (es) Anticuerpos anti-msr1 y métodos de uso de los mismos
BR0317898A (pt) Imunoterapia de malignidades de células b e doenças auto-imunes usando anticorpos não conjugados e conjugados, combinações de anticorpos e proteìnas de fusão
EP0778849A4 (en) POLYSPECIFIC IMMUNO-CONJUGATES AND ANTIBODY-COMPOSITE MOLECULES FOR THE TARGETED DETECTION OF THE DIFFERENT MEDICINE-RESISTANT PHENOTYPS
AR030631A1 (es) Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
HUP0102992A3 (en) Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
BG101024A (bg) Моноклонално антитяло срещу сd44v6
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
IE810451L (en) Tumour localization with labeled antibodies
ES2126145T3 (es) Redireccionamiento de anticuerpos.
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
DK1107795T3 (da) Thiomolybdat associeret med mindst ét carbohydrat og dets anvendelse til forebyggelse eller behandling af sygdomme kendetegnet ved aberrerende vascularisation, såsom cancer, maculadegeneration af våd type, rheumatoid arthritis
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
AU113858B2 (en) Improvements in or relating to preparations for covering the surface ofa road, roof orthe like
ES153953A1 (es) Perfeccionamientos introducidos en la fabricación de bujes para bicicletas, coches de niños, triciclos, carros de reparto, coches para inválidos y similares
ES76454U (es) Nuevo forjado de pisos y similares
GB402033A (en) Improvements in and relating to therapeutic agents
AU113220B2 (en) Improvements in and relating to surgical dressings, such as sanitary napkins, hospital pads andthe like
FR927089A (fr) Siège de lit particulièrement adapté pour malades et convalescents
ES23411U (es) Ampolla doble para medicamentos inyectables.
AU678732A (en) Improvements in and connected withthe catalytic treatment of organic and inorganic substances
CU20924A (es) Procedimiento para la purificacion del factor v humano y el antisuero anti factor v
ES105702A1 (es) Perfeccionamientos en la preparación de morteros de cemento y de fibras minerales y en el tratamiento de dichas fibras.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 938505

Country of ref document: ES